Press Releases

A Memorial Sloan Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates.

Memorial Sloan Kettering Cancer Center today unveiled a new pressroom for journalists with enhanced features as well as the availability of an on-site broadcast studio.

Patients with advanced kidney cancer can now take advantage of a new treatment option that has far fewer troubling side effects – this, according to a large, international trial led by Memorial Sloan Kettering Cancer Center investigators.

A new study by thoracic surgeons and pathologists at Memorial Sloan Kettering Cancer Center shows that a specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence.

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published in <em>The New England Journal of Medicine</em> and presented at the 49th Annual Meeting of the American Society of Clinical Oncology.

The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan Kettering Cancer Center research presented at the 49th annual meeting of the American Society of Clinical Oncology.

Foundation Medicine and Memorial Sloan Kettering Cancer Center today announced a partnership that brings together clinical, genomic and computational expertise to advance patient care in hematologic cancers.

Scientists from Memorial Sloan Kettering Cancer Center and Eureka Therapeutics have collaborated to create the new human monoclonal antibody, which targets a protein associated with many types of cancer and is of great interest to cancer researchers.